Tongyi Medicine completed the B round of financing, Huimei Capital led the investment
Tongyi Medicine is a pharmaceutical company dedicated to the development of a new generation of targeted tumor drugs. It has a multi-target ligand-drug conjugate (LDC) technology platform with independent intellectual property rights, and has a number of deadly targets for lung cancer, gastric cancer, liver cancer, etc. LDC drugs for the disease enter preclinical studies. […]
Tongyi Medicine completed the B round of financing, Huimei Capital led the investment Read More »